KalVista Pharmaceuticals, Inc. (KALV) intrinsic value & 10-year financials
KalVista Pharmaceuticals, Inc. (KALV) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 48.3%
- ROIC (10-yr avg)
- 12.0%
- Free cash flow (FY2025)
- -$153.3M
KALV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$183.4M | -$3.69 | -$153.3M | — | -252.5% |
| FY2024 | $50.0M | -$126.6M | -$3.44 | -$89.3M | -280.9% | -96.0% |
| FY2023 | — | -$92.9M | -$3.33 | -$76.5M | — | -81.1% |
| FY2022 | — | -$82.3M | -$3.36 | -$79.1M | — | -51.8% |
| FY2021 | — | -$46.2M | -$2.42 | -$30.3M | — | -41.3% |
| FY2020 | $12.7M | -$29.1M | -$1.64 | -$45.0M | -319.4% | -58.5% |
| FY2019 | $16.1M | -$20.8M | — | -$37.4M | -184.9% | -48.1% |
| FY2018 | $8.4M | -$15.8M | — | $9.1M | -222.8% | -63.9% |
| FY2017 | $1.5M | -$18.6M | — | -$23.8M | -1485.3% | 772.3% |
| FY2016 | $2.1M | -$11.4M | — | -$13.2M | -711.7% | 40.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
KalVista Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
KalVista Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -39.4% ROIC.
KalVista Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, KalVista Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-122.57 per share.